Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Acute Mountain Sickness
Interventions: Prochlorperazine Maleate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Evergreen, Colorado

Conditions: Sleep Apnea, Obstructive
Interventions: Oxytocin Intranasal Spray, Placebo Intranasal Spray; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cognitive Behavioral Therapy, Sleep Initiation and Maintenance Disorders, Sleep Deprivation, Sleep Disorders, Intrinsic
Interventions: firefighter Sleep Health Coaching Intervention (ffSHC), Control (Minimally Enhanced Usual Care); Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Type II
Interventions: High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Eating Disorders, Eating, Binge, Anorexia Nervosa/Bulimia, Eating Disorder Binge, Heart Rate Variability, Psychological Distress, Emotion Regulation, Autonomic Nervous System
Interventions: Baseline survey, Heart rate variability biofeedback, Educational materials; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions: Web-based psychoeducational resource; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
Interventions: Palliative Care, Standard of Care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Invasive Breast Cancer (Stage I-III), Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, Lobular Carcinoma, Fatigue Related to Cancer Treatment
Interventions: Naltrexone, Sugar Pill; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Interventions: CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
Interventions: Not listed
Lead sponsor: Mainz Biomed; Industry
Eligibility: 18 Years and older
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Parkinson Disease, Sexual Orientation
Interventions: Individual interviews, Focus Groups, National Survey; Other
Lead sponsor: Creighton University; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Ascites, Cirrhosis
Interventions: Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Cerebral Palsy
Interventions: reprogramming assisted communication device interface; Device
Lead sponsor: University of Southern California; Other
Eligibility: 5 Years to 25 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus
Interventions: Pyridostigmine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Risperidone ISM® 100 mg, Risperdal 4mg Tablet; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more

Conditions: Parkinson Disease
Interventions: Ropinirole oral product, Ropinirole Implant; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Orlando, Florida • Farmington Hills, Michigan • Kirkland, Washington

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity & Overweight, Obesity (Disorder)
Interventions: Positive Reinforcement, Positive Reinforcement + Areas for Change; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
Interventions: Obrixtamig, Pumitamig, Carboplatin, Etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Boston, Massachusetts • East Brunswick, New Jersey + 2 more

Conditions: Healthy Subjects
Interventions: Ultrasound scans; Other
Lead sponsor: Crossject; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Information Dissemination, Interprofessional Relations
Interventions: Discharge communication software, Usual care discharge process; Device · Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Interventions: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more

Conditions: Lung Cancer Screening, Lung Neoplasms, Smoking ( Cigarette), Early Detection of Cancer
Interventions: Empower LCS, Call+ Telephone Navigation, Usual Care, Education; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 57
States / cities: Anaheim, California • Costa Mesa, California • Irvine, California + 27 more

Conditions: Prostatic Neoplasm
Interventions: EZN-4176; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep

Evaluating Worksite Sleep Health Coaching in Firefighters: The Sleep Assistance for Firefighters Study

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

The Effects of Heart Rate Variability Biofeedback on College Students With Disordered Eating

Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence

Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test

Perspectives on Healthcare Access and Equity of People With Parkinson's Disease Identifying as LGBTQ+

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity

AchE Inhibitor and Insulin

Comparative Bioavailability of Risperidone.

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

Examining Valence-based Effects in Self-Monitoring Feedback Messages

A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

Echography Study_Anthropometric Measurements

Value of Technology to Transfer Discharge Information

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer